Confirmation of Release – PCK – PainChek Granted Patent in China – 14 August 2020
PainChek completes $10 million Placement – 11 August 2020
June 2020 Quarterly Update – 28 July 2020
Appendix 4E Preliminary Final Report to the Australian Securities Exchange – 30 June 2020
PainChek plans Canadian regulatory clearance and market entry – 10 June 2020
PainChek® granted Australian patent for pain assessment invention – 8th May 2020
Appendix 4C – Quarterly cash flow report for entities subject to Listing Rule 4.7B – 31 March 2020
PainChek submits FDA Pre-Submission Supplement- 14 April 2020
Coronavirus: Impact minimised by PCK’s digital business model – 12 March 202
PainChek® secures Japanese patent, progressing global expansion – 15 January 2020
Update on PainChek® business performance – 23 December 2019
PainChek UK confirms first orders, expands presence in the UK market – 3 December 2019
Appendix 4C – Quarterly report for entities subject to Listing Rule 4.7B – 30 September 2019
PainChek builds UK market presence, recruits Head of UK Business Development – 5 September 2019
PainChek® receives Singapore regulatory clearance 6 August 2019
2nd Tranche of Placement Received – 29 July 2019
Quarterly Update – April-June 2019
PainChek® granted US patent for pain assessment invention – July 24th 2019
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B – 31 March 2019
Quarterly Update – January to March 2019
Morrison Government $5m Grant for PainChek trial in Aged Care – 29 April 2019
Appendix 4D Half Year Report the Australian Securities Exchange (31 December 2018)
Quarterly Update: December 2018
PainChek® fast tracking UK commercialisation with trade award support- 10 December 2018
Uptake of new PainChek® app drives better quality aged care – 28th September 2018
PainChek® Investor update – 31st July 2018
Dr Jennifer Abbey joins PainChek Ltd clinical advisory board (4th June 2018)
PainChek™ receives FDA regulatory guidance (9th May 2018)
Quarterly Update January to March 2018 (24th April 2018)
PainChek Training Video (6th April 2018)
Appendix 4D Half Year Report to the Australian Securities Exchange (31st December 2017)
ePAT Technologies Ltd company name change to PainChek Ltd (15th December 2017)
Excellent performance of PainChek™ confirmed in second peer-review paper (13th December 2017)
PainChek™ Children’s App commercialization timelines on track (15th November 2017)
ePAT and PainChekTM continue to achieve commercial milestones (8th November 2017)
Quarterly Update (July – September 2017)
PainChek™ trademark and branding supports commercialisation drive (10th October 2017)
Melbourne 17th-20th October (26th September 2017)
ePAT Raises $3.75 million via Heavily Subscribed Placement (18th September 2017)
ePAT signs core strategic agreement with Dementia Support Australia DSA (6th September 2017)
Confirmation of Release – EPT – Appendix 3B
nViso agrees perpetual global license, takes strategic stake in ePAT (24th July 2017)
ePAT Pain Assessment App Secures Regulatory Clearance (19th July 2017)
New study validates face recognition app in pain detection (4 July 2017)
ePAT Technologies Ltd Investor Presentation (June 2017)
Third Quarter Report FY (2016/17)
Third Quarter – Appendix 4C (2016/17)
ASX announcement – IBM case study (March 2017)
Notice of AGM ePAT Technologies Limited (20th October 2016)
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
If you want to know more or withdraw your consent to all or some of the cookies, please refer to the Privacy Policy